A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
T cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral proteins 1,2 , combined with the Toll-like receptor 1/2 agonist XS15 emulsified in Montanide ISA51 VG, aiming to induce profound SARS-CoV-2 T cell immunity to combat COVID-19. Here we conducted a phase I open-label trial, recruiting 36 participants aged 18–80 years, who received a single subcutaneous CoVac-1 vaccination. The primary end point was safety analysed until day 56. Immunogenicity in terms of CoVac-1-induced T cell response was analysed as the main secondary end point until day 28 and in the follow-up until month 3. No serious adverse events and no grade 4 adverse events were observed. Expected local granuloma formation was observed in all study participants, whereas systemic reactogenicity was absent or mild. SARS-CoV-2-specific T cell responses targeting multiple vaccine peptides were induced in all study participants, mediated by multifunctional T helper 1 CD4 + and CD8 + T cells. CoVac-1-induced IFNγ T cell responses persisted in the follow-up analyses and surpassed those detected after SARS-CoV-2 infection as well as after vaccination with approved vaccines. Furthermore, vaccine-induced T cell responses were unaffected by current SARS-CoV-2 variants of concern. Together, CoVac-1 showed a favourable safety profile and induced broad, potent and variant of concern-independent T cell responses, supporting the presently ongoing evaluation in a phase II trial for patients with B cell or antibody deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
Shedlock, D. J., & Shen, H. (2003) · Science · doi:10.1126/science.1082305 · Cited by 1,460
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03944-y · Cited by 1,337
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2598-9 · Cited by 1,310
Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034201 · Cited by 1,208
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., et al. (2020) · Science · doi:10.1126/science.abd3871 · Cited by 1,120
Lee, L. Y., Cazier, J.-B., Angelis, V., Arnold, R., Bisht, V., Campton, N. A., Chackathayil, J., Cheng, V. W., Curley, H. M., Fittall, M. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31173-9 · Cited by 1,103
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load
Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E., Reddy, S., de Pierres, C., Mncube, Z., Mkhwanazi, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1520 · Cited by 1,032
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938
Self-citationWeiskopf, D., Schmitz, K. S., Raadsen, M. P., Grifoni, A., Okba, N. M. A., Endeman, H., van den Akker, J. P. C., Molenkamp, R., Koopmans, M. P. G., van Gorp, E. C. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd2071 · Cited by 907
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
Ng, K. W., Faulkner, N., Cornish, G. H., Rosa, A., Harvey, R., Hussain, S., Ulferts, R., Earl, C., Wrobel, A. G., Benton, D. J., et al. (2020) · Science · doi:10.1126/science.abe1107 · Cited by 886
Tan, A. T., Linster, M., Tan, C. W., Le Bert, N., Chia, W. N., Kunasegaran, K., Zhuang, Y., Tham, C. Y. L., Chia, A., Smith, G. J. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108728 · Cited by 740
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Rodda, L. B., Netland, J., Shehata, L., Pruner, K. B., Morawski, P. A., Thouvenel, C. D., Takehara, K. K., Eggenberger, J., Hemann, E. A., Waterman, H. R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.029 · Cited by 647
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Herishanu, Y., Avivi, I., Aharon, A., Shefer, G., Levi, S., Bronstein, Y., Morales, M., Ziv, T., Shorer Arbel, Y., Scarfò, L., et al. (2021) · Blood · doi:10.1182/blood.2021011568 · Cited by 614
Monin, L., Laing, A. G., Muñoz-Ruiz, M., McKenzie, D. R., del Molino del Barrio, I., Alaguthurai, T., Domingo-Vila, C., Hayday, T. S., Graham, C., Seow, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00213-8 · Cited by 611
Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00628-0 · Cited by 603
Expanding the effector CD4 T-cell repertoire: the Th17 lineage
Harrington, L. E., Mangan, P. R., & Weaver, C. T. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.03.017 · Cited by 590
Yang, K., Sheng, Y., Huang, C., Jin, Y., Xiong, N., Jiang, K., Lu, H., Liu, J., Yang, J., Dong, Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30310-7 · Cited by 584
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
Nelde, A., Bilich, T., Heitmann, J. S., Maringer, Y., Salih, H. R., Roerden, M., Lübke, M., Bauer, J., Rieth, J., Wacker, M., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00808-x · Cited by 582
Self-citationTarke, A., Sidney, J., Kidd, C. K., Dan, J. M., Ramirez, S. I., Yu, E. D., Mateus, J., da Silva Antunes, R., Moore, E., Rubiro, P., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100204 · Cited by 540
Liu, X., Shaw, R. H., Stuart, A. S. V., Greenland, M., Aley, P. K., Andrews, N. J., Cameron, J. C., Charlton, S., Clutterbuck, E. A., Collins, A. M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01694-9 · Cited by 491
Myers, L. C., Parodi, S. M., Escobar, G. J., & Liu, V. X. (2020) · JAMA · doi:10.1001/jama.2020.7202 · Cited by 467
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Platten, M., Bunse, L., Wick, A., Bunse, T., Le Cornet, L., Harting, I., Sahm, F., Sanghvi, K., Tan, C. L., Poschke, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03363-z · Cited by 432
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
Wu, K., Werner, A. P., Koch, M., Choi, A., Narayanan, E., Stewart-Jones, G. B. E., Colpitts, T., Bennett, H., Boyoglu-Barnum, S., Shi, W., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102179 · Cited by 409
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover
Soresina, A., Moratto, D., Chiarini, M., Paolillo, C., Baresi, G., Focà, E., Bezzi, M., Baronio, B., Giacomelli, M., & Badolato, R. (2020) · Pediatric Allergy and Immunology · doi:10.1111/pai.13263 · Cited by 327
Direct Link Between mhc Polymorphism, T Cell Avidity, and Diversity in Immune Defense
Messaoudi, I., Patiño, J. A. G., Dyall, R., LeMaoult, J., & Nikolich-Žugich, J. (2002) · Science · doi:10.1126/science.1076064 · Cited by 323
Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines
Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S., & Ganne, V (2002) · Expert Review of Vaccines · doi:10.1586/14760584.1.1.111 · Cited by 308
Deming, D., Sheahan, T., Heise, M., Yount, B., Davis, N., Sims, A., Suthar, M., Harkema, J., Whitmore, A., Pickles, R., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030525 · Cited by 275
Gallais, F., Velay, A., Nazon, C., Wendling, M.-J., Partisani, M., Sibilia, J., Candon, S., & Fafi-Kremer, S. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2701.203611 · Cited by 267
Cellular and Humoral Immunity against Vaccinia Virus Infection of Mice
Xu, R., Johnson, A. J., Liggitt, D., & Bevan, M. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6265 · Cited by 260
Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., Kase, R., Sekiguchi, S., Morita, K., Hishima, T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6337 · Cited by 252
Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees
Yadav, P. D., Sapkal, G. N., Abraham, P., Ella, R., Deshpande, G., Patil, D. Y., Nyayanit, D. A., Gupta, N., Sahay, R. R., Shete, A. M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab411 · Cited by 251
Carvalho, L. H., Sano, G.-I., Hafalla, J. C. R., Morrot, A., de Lafaille, M. A. C., & Zavala, F. (2002) · Nature Medicine · doi:10.1038/nm0202-166 · Cited by 251
Lee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuge, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3836 · Cited by 244
Rini, B. I., Stenzl, A., Zdrojowy, R., Kogan, M., Shkolnik, M., Oudard, S., Weikert, S., Bracarda, S., Crabb, S. J., Bedke, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30408-9 · Cited by 220
Sette, A., Moutaftsi, M., Moyron-Quiroz, J., McCausland, M. M., Davies, D. H., Johnston, R. J., Peters, B., Rafii-El-Idrissi Benhnia, M., Hoffmann, J., Su, H.-P., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.018 · Cited by 168
Bilich, T., Nelde, A., Heitmann, J. S., Maringer, Y., Roerden, M., Bauer, J., Rieth, J., Wacker, M., Peter, A., Hörber, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf7517 · Cited by 156
Self-citationSafety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine
Atsmon, J., Kate-Ilovitz, E., Shaikevich, D., Singer, Y., Volokhov, I., Haim, K. Y., & Ben-Yedidia, T. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9632-5 · Cited by 148
CD4+ cytolytic T cell clone confers protection against murine malaria.
Tsuji, M., Romero, P., Nussenzweig, R. S., & Zavala, F. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.5.1353 · Cited by 146
Iwata-Yoshikawa, N., Uda, A., Suzuki, T., Tsunetsugu-Yokota, Y., Sato, Y., Morikawa, S., Tashiro, M., Sata, T., Hasegawa, H., & Nagata, N. (2014) · Journal of Virology · doi:10.1128/jvi.00983-14 · Cited by 135
van Doorn, E., Liu, H., Huckriede, A. L. W., & Hak, E. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1071455 · Cited by 132
van de Berg, P. J., van Leeuwen, E. M. M., ten Berge, I. J. M., & van Lier, R. A. W. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.007 · Cited by 128
Fully Functional Memory CD8 T Cells in the Absence of CD4 T Cells
Marzo, A. L., Vezys, V., Klonowski, K. D., Lee, S., Muralimohan, G., Moore, M. W., Tough, D. F., & Lefrançois, L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.969 · Cited by 125
Feyerabend, S., Stevanovic, S., Gouttefangeas, C., Wernet, D., Hennenlotter, J., Bedke, J., Dietz, K., Pascolo, S., Kuczyk, M., Rammensee, H., et al. (2009) · The Prostate · doi:10.1002/pros.20941 · Cited by 107
Self-citationNoguchi, M., Kobayashi, K., Suetsugu, N., Tomiyasu, K., Suekane, S., Yamada, A., Itoh, K., & Noda, S. (2003) · The Prostate · doi:10.1002/pros.10276 · Cited by 101
Mlcochova, P., Kemp, S., Dhar, M. S., Papa, G., Meng, B., Mishra, S., Whittaker, C., Mellan, T., Ferreira, I., Datir, R., et al. (2021) · doi:10.1101/2021.05.08.443253 · Cited by 90
Sato, Y., Shomura, H., Maeda, Y., Mine, T., Une, Y., Akasaka, Y., Kondo, M., Takahashi, S., Shinohara, T., Katagiri, K., et al. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01522.x · Cited by 70
Rammensee, H., Wiesmüller, K.-H., Chandran, P. A., Zelba, H., Rusch, E., Gouttefangeas, C., Kowalewski, D. J., Marco, M. D., Haen, S. P., Walz, J. S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0796-5 · Cited by 70
Self-citationElyaman, W., Kivisäkk, P., Reddy, J., Chitnis, T., Raddassi, K., Imitola, J., Bradshaw, E., Kuchroo, V., Yagita, H., Sayegh, M., et al. (2008) · American Journal of Pathology · doi:10.2353/ajpath.2008.080142 · Cited by 67
Class II-Restricted Protective Immunity Induced by Malaria Sporozoites
Oliveira, G. A., Kumar, K. A., Calvo-Calle, J. M., Othoro, C., Altszuler, D., Nussenzweig, V., & Nardin, E. H. (2008) · Infection and Immunity · doi:10.1128/iai.00566-07 · Cited by 61
Tan, A. C. L., La Gruta, N. L., Zeng, W., & Jackson, D. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100664 · Cited by 51
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Bilich, T., Roerden, M., Maringer, Y., Nelde, A., Heitmann, J. S., Dubbelaar, M. L., Peter, A., Hörber, S., Bauer, J., Rieth, J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0191 · Cited by 44
Self-citationKemball, C. C., Pack, C. D., Guay, H., Li, Z.-N., Steinhauer, D. A., Szomolanyi‐Tsuda, E., & Lukacher, A. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.1113 · Cited by 40
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups
Rammensee, H., Gouttefangeas, C., Heidu, S., Klein, R., Preuß, B. E., Walz, J. S., Nelde, A., Haen, S. P., Reth, M. G., Yang, J., et al. (2021) · Vaccines · doi:10.3390/vaccines9050428 · Cited by 29
Self-citationPre-existing and post-COVID-19 immune responses to SARS-CoV-2 in cancer patientsPreprint
Bilich, T., Roerden, M., Maringer, Y., Nelde, A., Heitmann, J. S., Dubbelaar, M. L., Peter, A., Hörber, S., Bauer, J., Rieth, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-237290/v1 · Cited by 2
Self-citation
Cited by
The T cell immune response against SARS-CoV-2
Moss, P. (2022) · Nature Immunology · doi:10.1038/s41590-021-01122-w · Cited by 1,235
Decoding Toll-like receptors: Recent insights and perspectives in innate immunity
Kawai, T., Ikegawa, M., Ori, D., & Akira, S. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.004 · Cited by 528
Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139
Backlund, C. M., Holden, R. L., Moynihan, K. D., Garafola, D., Farquhar, C., Mehta, N. K., Maiorino, L., Pham, S., Iorgulescu, J. B., Reardon, D. A., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204078119 · Cited by 61
Palmer, C. D., Scallan, C. D., Kraemer Tardif, L. D., Kachura, M. A., Rappaport, A. R., Koralek, D. O., Uriel, A., Gitlin, L., Klein, J., Davis, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39053-9 · Cited by 42
Metadata
- Authors
- Heitmann, J. S., Bilich, T., Tandler, C., Nelde, A., Maringer, Y., Marconato, M., Reusch, J., Jäger, S., Denk, M., Richter, M., Anton, L., Weber, L. M., Roerden, M., Bauer, J., Rieth, J., Wacker, M., Hörber, S., Peter, A., Meisner, C., Fischer, I., Löffler, M. W., Karbach, J., Jäger, E., Klein, R., Rammensee, H.-G., Salih, H. R., & Walz, J. S.
- Venue
- Nature
- Published
- 2021-11-23
- Volume
- 601
- Issue
- 7894
- Pages
- 617-622
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3215049942
- Cited by
- 255
- References
- 72
- FWCI
- 14.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.